EOLS Evolus Inc.

-2.35  -10%
Previous Close 24.01
Open 23.8
Price To Book 7.01
Market Cap 590776305
Shares 27,274,991
Volume 1,119,247
Short Ratio
Av. Daily Volume 1,368,668

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced February 1, 2019.
Glabellar lines

Latest News

  1. Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
  2. Evolus Announces Publication of U.S. Phase III Pivotal Trial Results for Jeuveau™ in Dermatologic Surgery
  3. NASH, Allergies and Beauty Stocks: Invest or Not?
  4. Why Evolus Stock Is Soaring 12% Higher Today
  5. Evolus Reports Fourth Quarter and Full Year 2018 Results
  6. Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC
  7. Evolus to Release Fourth Quarter and Full Year 2018 Financial Results and Provide a Business Update on Monday, March 18, 2019
  8. Evolus, Inc.’s (NASDAQ:EOLS) Path To Profitability
  9. Implied Volatility Surging for Evolus (EOLS) Stock Options
  10. Evolus Appoints Crystal Muilenburg as Vice President Corporate Communications & Public Relations
  11. 2 Frustrating Flops, Plus Welcome to the Wrinkle Wars
  12. Allergan Responds to Investor's Call for CEO/Chair Role Split
  13. Harry Boxer’s stocks to watch include maker of Botox competitor
  14. Evolus Stockholders May Be Frowning in the Short Run
  15. Cramer Remix: If the market drops tomorrow, buy this stock
  16. Aesthetics company behind latest Botox rival was 'designed' to compete with Botox: CEO
  17. Why Leggett & Platt, Mueller Industries, and Evolus Jumped Today
  18. Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management
  19. Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
  20. Papa John's, Evolus rise; Gannett, Allergan slip